NCT05765604View on ClinicalTrials.gov

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

July 30, 2023

Study Completion Date

March 30, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant COVID-19 variant vaccine(Sf9 cell)

IM

BIOLOGICAL

Recombinant COVID-19 vaccine(CHO cell)

IM

Trial Locations (1)

Unknown

Jiangsu Provincial Center for Disease Control, Taizhou

All Listed Sponsors
lead

WestVac Biopharma Co., Ltd.

INDUSTRY